Management Team

Andrew Hall, B. Med. Sci., M.Sc.

Chief Executive Officer

Andrew brings more than 20 years of executive experience in biopharmaceuticals and life science. He has spent his career focused on corporate and portfolio strategy, as well as business development and commercial operations with industry leaders such as Celgene, Merck, Schering-Plough and Bristol-Meyers Squibb, spearheading new product development, analytics and commercial strategy for immunology & inflammation, oncology, women's health, cardiovascular portfolios and more. In his most recent roles with Celgene, Andrew had led new product analytics and commercial strategy for the Inflammation & Immunology division and led new critical alliances across all therapeutic areas. He joined IMV as Chief Business Officer in 2020 and became the Company’s CEO in January 2021. Andrew Hall holds a Master of Science from RMIT University and a Bachelor of Medical Science with Honors from Melbourne University.

Brittany Davison, CPA, CA

Chief Accounting Officer

With over 10 years of financial reporting experience, Brittany has provided key financial and operational leadership to IMV since she began working for the company in February 2014. She is responsible for financial reporting, tax and securities compliance, managing audit and internal control functions, investor relations and IT oversight. Prior to joining the company, she began her career as an audit senior at Grant Thornton. Brittany graduated summa cum laude with a Bachelor of Commerce degree from Saint Mary’s University and is a Chartered Professional Accountant. Brittany volunteers with the Mental Health Foundation of Nova Scotia and is actively involved in the Atlantic Chapter of Financial Executives International.

Jeremy Graff, PhD

Chief Scientific Officer

Dr. Graff brings over 20 years of experience in preclinical, translational research and clinical development for novel Cancer therapeutics and joined IMV in June 2021 as Chief Scientific Officer. Most recently, Dr. Graff served as Chief Development Officer and Senior Vice President, Research at HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis. At HiberCell, heled the scientific and clinical development teams. Prior to that he served as President and Chief Scientific Officer for Biothera Pharmaceuticals (2018-2020)starting Chief Scientific Officer (2014-2018). In these executive roles, Dr. Graff was responsible for the strategic design of the Biothera clinical program. He also led corporate strategy and investor engagement. Ultimately, he orchestrated the acquisition of Biothera and its lead asset, Imprime PGG, by HiberCell, Inc in 2020. Prior to leaping into Biotech, Dr. Graff spent nearly 17 years at Eli Lilly and Company, delivering multiple novel therapies to the clinic. His extensive experience in Cancer Drug Discovery and Development, immuno-oncology, biomarker discovery and patient stratification culminated in designing, developing and leading the Translational Oncology group Unit to improve the technical success of Lilly’s Oncology portfolio. At Lilly Research Labs (LRL), he was the recipient of the LRL President’s Recognition Award, the Company’s highest annual award. Dr. Graff received a Ph.D. from the University of Kentucky’s Markey Cancer Center and completed a post-doctoral fellowship at the John Hopkins University Oncology Center. He has authored more than 60 peer-reviewed publications that have collectively garnered more than 20,000 research citations and holds a number of patents for novel cancer therapies. He has also served for nearly a decade on the editorial board for Cancer Research, the flagship journal for the American Association for Cancer Research.

Marie-Eve Charrois, MA

Vice President, Quality, Regulatory Affairs and Pharmacovigilance

Marie-Eve is in charge of developing the regulatory dossier and obtaining the required authorization to achieve IMV’s clinical programs. She also oversees the pharmacovigilance and activities related to the clinical safety of the investigational products used in IMV sponsored clinical trials. She brings 25 years of experience in research and in the biopharmaceutical industry. She developed an expertise in supporting the clinical development and ensuring the regulatory compliance of several types of innovative biologics and licensed vaccines. During her 18-year experience at Medicago (a biotech company developing Virus-Like Particle vaccine), she has served in many roles of increasing responsibility in Research, Quality, and Regulatory Affairs, and the five last years as Director of Regulatory Affairs. As Site Conformance Manager at GSK Vaccine (Quebec City facility), she has played an active role in the development of regulatory strategies for the implementation of changes to the licensed manufacturing process and obtaining the necessary approval to allow the Seasonal Influenza vaccine to be released and delivered in time. She was also in charge of the preparation for GMP inspections by the GSK Global Quality organization and the Regulatory Agencies. Over her career, she was involved in the preparation of the regulatory dossier to support several Phase 1, 2, and 3 clinical trials conducted in Canada, USA, Europe, South Africa, and Australia. She has actively participated in formal and technical meetings with regulatory authorities (FDA, Health Canada BRDD, and EMEA) in the context of the vaccine development, and also in the context of regulatory interactions associated with the maintenance of licensed vaccines. Marie-Eve also successfully contributed to the development of the CMC/Quality sections of submission packages for license applications (BLA in US and NDS in Canada) and post-approval changes. More recently, she was selected in the first cohort of the Excellence in Canadian Board Governance (ECBG) Program from the McGill University Executive Institute and completed the program developed in collaboration with Executive Women in Bio (WIB - Greater Montreal). Marie-Eve also owns a Master of Arts from Laval University in Quebec.

Stéphan Fiset, MSc, MBA

Vice President, Clinical Research

Stephan manages the implementation and progress of IMV’s clinical programs since 2007. Prior to joining the company, he worked for more than 15 years in clinical research with Medicago, GlaxoSmithKline and the Infectious Disease Research Center of the CHUL, where he led multifunctional teams in several therapeutic areas, including Oncology, HIV, Vaccines, Sepsis, Hematology, and Neurology. Throughout his career, he was involved in scientific and operational activities of several Phase I to Phase III trials. He has also led several process improvement teams to ensure timely and cost-effective delivery of clinical trials. Stephan received an MBA with honor from Université Laval and a Master degree in Microbiology from the University of Sherbrooke.